Emily Chang, MD
Nephrology · Sanford, NCNPI 1447456512
Payments from drug & device makers
What this record shows
19 manufacturers reported payments, led by Lantheus Medical Imaging, Inc. at 59.6% of the total. Reporting peaked in 2020 at $3,000 and has fallen 81.9% since, to $542 in 2025.
Across 58 payments — averaging $86.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lantheus Medical Imaging, Inc.$3K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$571
- Vifor Pharma, Inc.$305
- Calliditas Therapeutics US Inc.$202
- Boehringer Ingelheim$195
- Amgen$126
- plus $634 from 13 others
Across 34 payments — averaging $6669.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lantheus Medical Imaging, Inc.$150K
- AbbVie$39K
- Fresenius USA Marketing, Inc.$38K
What the payments were for
- Consulting fees$3,00060%
- Food & beverage$2,03340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lantheus Medical Imaging, Inc. | 1 | $3,000 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 9 | $571 |
| Vifor Pharma, Inc. | 7 | $305 |
| Calliditas Therapeutics US Inc. | 4 | $202 |
| Boehringer Ingelheim | 3 | $195 |
| Amgen | 5 | $126 |
| Otsuka America Pharmaceutical, Inc. | 5 | $126 |
| Novartis | 4 | $100 |
| AstraZeneca | 4 | $80 |
| Novo Nordisk | 3 | $78 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| GSK | 2 | $43 |
| Bayer | 2 | $39 |
| Travere Therapeutics, Inc. | 2 | $24 |
| Lilly USA, LLC | 1 | $21 |
| Ardelyx, Inc. | 1 | $21 |
| Sanofi | 1 | $20 |
| Philips North America LLC | 1 | $20 |
| Fresenius USA Marketing, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,033 in reported general payments places this provider in the 75th percentile of 366 nephrology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 31 | $49,775 |
| OzempicSemaglutide | 25 | $32,298 |
| FarxigaDapagliflozin Propanediol | 14 | $22,630 |
| VeltassaPatiromer Calcium Sorbitex | 13 | $15,022 |
| RetacritEpoetin Alfa-Epbx | 11 | $6,479 |
| Sevelamer Carbonate | 22 | $2,324 |
| Nifedipine ErNifedipine | 14 | $1,012 |
| Magnesium Sulfate | 20 | $736 |
| Chlorthalidone | 44 | $586 |
| Losartan Potassium | 57 | $492 |
| Amlodipine Besylate | 73 | $491 |
| Lisinopril | 66 | $451 |
| Furosemide | 116 | $443 |
| Atorvastatin Calcium | 46 | $381 |
| Tamsulosin Hcl | 25 | $380 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $195 | $49,77531 claims |
| Novo NordiskOzempic | $78 | $32,29825 claims |
| AstraZenecaFarxiga | $80 | $22,63014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 366 nephrology providers in North Carolina.
Other nephrology in Sanford
- Raven VooraSanford$111K
- Amy MottlSanford$39K
- Manish SahaSanford$16K
- Gregory GreenwoodWinston-Salem$947K
- Michael EtomiCharlotte$212K
- William KendrickGreenville$125K
- Jason EckelCary$123K
- Nam VoAsheville$89K
- Jennifer StoddardPinehurst$77K
- Barry FreedmanWinston Salem$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.